Association between epstein-barr virus infection and chemoresistance to docetaxel in gastric carcinoma

Molecules and Cells

Volumn 32, Issue 2, 2011, Pages 173-179

  Shin, Hee Jong ^a   Kim, Do Nyun ^a   Lee, Suk Kyeong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Cell cycle related genes; Chemoresistance; Docetaxel; EBV positive gastric carcinoma

Indexed keywords

CASPASE; DOCETAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; SURVIVIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESISTANCE; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; STOMACH CARCINOMA; WESTERN BLOTTING;

CARCINOMA; CELL LINE, TRANSFORMED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TAXOIDS;

HUMAN HERPESVIRUS 4;

EID: 81055157125     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-011-0066-y     Document Type: Article

References (38)

1. Abbas, T., and Dutta, A. (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400-414.
2. Akiba, S., Koriyama, C., Herrera-Goepfert, R., and Eizuru, Y. (2008). Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 99, 195-201. (Pubitemid 351228470)
3. Bornkamm, G.W., and Hammerschmidt, W. (2001). Molecular virology of Epstein-Barr virus. Phil. Trans. R. Soc. B. 356, 437-459. (Pubitemid 32442745)
4. Burke, A.P., Yen, T.S., Shekitka, K.M., and Sobin, L.H. (1990). Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod. Pathol. 3, 377-380.
5. Chou, S.P., Tsai, C.H., Li, L.Y., Liu, M.Y., and Chen, J.Y. (2004). Characterization of monoclonal antibody to the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2. Hybrid Hybridomics 23, 29-37.
6. Daibata, M., Bandobashi, K., Kuroda, M., Imai, S., Miyoshi, I., and Taguchi, H. (2005). Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. J. Virol. 79, 5875-5879. (Pubitemid 40548258)
7. Desbien, A.L., Kappler, J.W., and Marrack, P. (2009). The Epstein- Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim. Proc. Natl. Acad. Sci. USA 106, 5663-5668.
8. Feng, W.H., Israel, B., Raab-Traub, N., Busson, P., and Kenney, S.C. (2002). Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62, 1920-1926. (Pubitemid 34408523)
9. Feng, W.H., Hong, G., Delecluse, H.J., and Kenney, S.C. (2004). Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78, 1893-1902. (Pubitemid 38176721)
10. He, Y., Cai, S., Zhang, G., Li, X., Pan, L., and Du, J. (2008). Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus Res. 135, 175-180.
11. Hino, R., Uozaki, H., Inoue, Y., Shintani, Y., Ushiku, T., Sakatani, T., Takada, K., and Fukayama, M. (2008). Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res. 68, 1427-1435. (Pubitemid 351346850)
12. Hino, R., Uozaki, H., Murakami, N., Ushiku, T., Shinozaki, A., Ishikawa, S., Morikawa, T., Nakaya, T., Sakatani, T., Takada, K., et al. (2009). Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69, 2766-2774.
13. Huang, H., Pan, X., Zhou, S., Li, Z., Yu, L., Kong, X., and Zheng, Q. (1999). Flow cytometric analysis of BHRF1 expression prohibiting apoptosis induced by radiation. Ann. Otol. Rhinol. Laryngol. 108, 481-484.
14. Imai, S., Koizumi, S., Sugiura, M., Tokunaga, M., Uemura, Y., Yamamoto, N., Tanaka, S., Sato, E., and Osato, T. (1994). Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl. Acad. Sci. USA 91, 9131-9135.
15. Jeon, J.P., Nam, H.Y., Shim, S.M., and Han, B.G. (2009). Sustained viral activity of Epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol. Cells 27, 143-148.
16. Jones, K., Nourse, J., Corbett, G., and Gandhi, M.K. (2010). Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific Tcell immunity. Int. J. Lab. Hematol. 32, e169-174.
17. Jung, E.J., Lee, Y.M., Lee, B.L., Chang, M.S., and Kim, W.H. (2007a). Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virusinfected gastric carcinoma cell line. Anticancer Drugs 18, 79-85.
18. Jung, E.J., Lee, Y.M., Lee, B.L., Chang, M.S., and Kim, W.H. (2007b). Lytic induction and apoptosis of Epstein-Barr virusassociated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Lett. 247, 77-83. (Pubitemid 44959412)
19. Lee, H.S., Chang, M.S., Yang, H.K., Lee, B.L., and Kim, W.H. (2004). Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epsteinbarr virus-negative carcinoma. Clin. Cancer Res. 10, 1698-1705. (Pubitemid 38435561)
20. Liu, T.Y., Wu, S.J., Huang, M.H., Lo, F.Y., Tsai, M.H., Tsai, C.H., Hsu, S.M., and Lin, C.W. (2010). EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Mol. Cancer 9, 32.
21. Lu, J., Murakami, M., Verma, S.C., Cai, Q., Haldar, S., Kaul, R., Wasik, M.A., Middeldorp, J., and Robertson, E.S. (2011). Epstein- Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 410, 64-75.
22. Luo, B., Wang, Y., Wang, X.F., Liang, H., Yan, L.P., Huang, B.H., and Zhao, P. (2005). Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J. Gastroenterol. 11, 629-633. (Pubitemid 40220748)
23. Lyseng-Williamson, K.A., and Fenton, C. (2005). Docetaxel: a review of its use in metastatic breast cancer. Drugs 65, 2513-2531. (Pubitemid 41697318)
24. Mei, Y.P., Zhou, J.M., Wang, Y., Huang, H., Deng, R., Feng, G.K., Zeng, Y.X., and Zhu, X.F. (2007). Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6, 1379-1385. (Pubitemid 47327973)
25. Oh, S.T., Seo, J.S., Moon, U.Y., Kang, K.H., Shin, D.J., Yoon, S.K., Kim, W.H., Park, J.G., and Lee, S.K. (2004). A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 320, 330-336. (Pubitemid 38315158)
26. Pathan, N., Aime-Sempe, C., Kitada, S., Basu, A., Haldar, S., and Reed, J.C. (2001). Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia 3, 550-559. (Pubitemid 33151022)
27. Peng, M., and Lundgren, E. (1992). Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7, 1775-1782.
28. Rickinson, A.B., and Kieff, E.(2001). Epstein-Barr virus. In Field's Virology, B.M. Knipe, and P.M. Howley, eds. (Philadelphia, USA: Lippincott Williams and Wilkins), pp. 2575-2627.
29. Shibata, D., and Weiss, L.M. (1992). Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769-774.
30. Shimizu, N., Yoshiyama, H., and Takada, K. (1996). Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBVnegative Akata cells. J. Virol. 70, 7260-7263. (Pubitemid 26307449)
31. Speck, S.H., and Ganem, D. (2010). Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 8, 100-115.
32. Takada, K. (2000). Epstein-Barr virus and gastric carcinoma. Mol. Pathol. 53, 255-261.
33. van Beek, J., zur Hausen, A., Kranenbarg, E.K., Warring, R.J., Bloemena, E., Craanen, M.E., van de Velde, C.J., Middeldorp, J.M., Meijer, C.J., and van den Brule, A.J. (2002). A rapid and reliable enzyme immunoassay PCR-based screening method to identify EBV-carrying gastric carcinomas. Mod. Pathol. 15, 870-877. (Pubitemid 34919780)
34. Vicat, J.M., Ardila-Osorio, H., Khabir, A., Brezak, M.C., Viossat, I., Kasprzyk, P., Jlidi, R., Opolon, P., Ooka, T., Prevost, G., et al. (2003). Apoptosis and TRAF-1 cleavage in Epstein-Barr viruspositive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor. Biochem. Pharmacol. 65, 423-433. (Pubitemid 36084559)
35. Westphal, E.M., Blackstock, W., Feng, W., Israel, B., and Kenney, S.C. (2000). Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60, 5781-5788.
36. Wolf, H., Bogedain, C., and Schwarzmann, F. (1993). Epstein-Barr virus and its interaction with the host. Intervirology 35, 26-39. (Pubitemid 23241056)
37. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51. (Pubitemid 46020826)
38. Yvon, A.M., Wadsworth, P., and Jordan, M.A. (1999). Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947-959. (Pubitemid 29193723)